XiaoMi-AI文件搜索系统
World File Search Systemdemonstrated
青少年如何使用音乐使他们的心理受益...
This paper aims to discover techniques in which music can be used to treat anxiety and depressioninadolescents.Studieshavedemonstratedthatmusicplaysasignificantroleacrossculturesin affectingmood,performance,andphysiologicalfunctions.Focusingonadolescents'mentalhealth,this researchfurtherexploresthesefindingsandlooksattheaspectsofmusicthathavethepowertochange one'smentalandphysicalstate.Thispapercoversfourtopics:aliteraturereview,researchmethods,the surveyconducted,andaconclusionthataimstoconnectcurrentknowledgewithobservationsfromthe survey. These findings connect music's effectiveness in使个人平静或振奋人心的偏好文化，建议您的核心术语，持有的心理学精神。
Cadth报销建议
Evidence from one open-label phase III randomized controlled trial involving a total of 886 patients with locally advanced or metastatic urothelial cancer (Study EV-302) showed that treatment with enfortumab vedotin in combination with pembrolizumab demonstrated a clinically meaningful benefit compared to platinum plus gemcitabine chemotherapy (PLAT + GEM) in improving overall survival (HR: 0.468 [95% CI: 0.376，0.582]; p <0.00001），无进展生存率（HR = 0.450，95％CI：0.377，0.538; p <0.00001）和客观响应率（差异= 23.3％[95％CI，16.8％至29.6％]；Enfortumab Vedotin与Pembrolizumab结合使用的安全性与Enfortumab Vedotin单一疗法和pembrolizumab单一疗法的已知安全概况一致。
兼职登记护士（急诊和家庭分娩中心）职位发布编号：2408144发布日期：2024年8月9日至2024年8月15日，RAT
兼职注册护士（急诊和家庭分娩中心）职位发布编号：2408144发布日期：2024年8月9日至2024年8月15日，薪水率：参考ONA集体协议时间表：兼职时间分配时间表：Walkerton申请地点：目前正在为急性护理和家庭灰色居民的兼职护士置于Walkerton Center的兼职护士职位。电子邮件，临床应用，内部/互联网•知识和遵守职业健康与安全，感染控制以及健康中心政策和程序Applicants must meet the following criteria: • Registered with the Ontario College of Nurses as a Registered Nurse • Diploma/Degree from a recognized College/University, BScN preferred • Recent Acute Care and Obstetrical experience preferred • Excellent organizational and problem solving skills with an ability to set priorities • Demonstrated strong patient/family health teaching skills • Demonstrated effective professional, interpersonal, and therapeutic communication skills required • Strong critical thinking, assessment, observation,人际交往，促进和沟通能力•透彻了解护理原则，并根据护理实践的标准以及进入注册护士的练习能力，安大略省和法规的练习能力的能力，并获得了受监管的健康职业的法规的能力•室内的知识和维护能力：启动和维持血液的能力：给药，血糖监测，鼻腔管，伤口管理技能，常规和其他感染控制预防措施，正常和异常的实验室价值观•表现出以协作的团队方式和遵守个人行为标准的能力和渴望积极的工作和出勤记录是必不可少的•持续专业发展的证据•需要基本的计算机素养，例如
新闻稿，2025年1月21日，韩国授予Diamyd Medical的Precision Medicine in Autommune Diabetes
1st-line benefit in combination with widely approved CDK4/6 inhibitors Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically significant and clinically meaningful无进展生存期（PFS）的主要终点的改善。该试验评估了切换到芳香酶抑制剂（AI）（ANASTROZOLE或LETROOZOLE）与CDK4/6抑制剂在一线治疗激素受体（HR）患者（HR）蛋白（HR） - 蛋白蛋白酶（Her2）型乳腺较大较大的癌症中的一线治疗中，与CDK4/6抑制剂结合使用了CDK4/6抑制剂，将切换到持续的护理标准治疗。
新闻发布Sarclisa在中国获得了首次批准，用于治疗成年患者的复发或难治性多发性骨髓瘤
• Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa and the standard treatment Pd, improved responses and long-term outcomes compared to Pd alone in R/R MM patients • Sarclisa-Pd is currently recommended by the Chinese Society of Clinical Oncology ( CCSCO) and Chinese Anti-Cancer Association ( CACA) treatment该患者人口巴黎的指南，2025年1月13日。中国国家医学产品管理局（NMPA）批准了一种抗CD38药物Sarclisa，并结合了Pomalidomide和Pomalidomide和Dexamethasone（PD），用于治疗多发性骨髓瘤患者（MM），他们至少接受了一种先前的治疗疗法，包括Lenalidomide和蛋白酶蛋白酶体内的蛋白酶疗法和蛋白酶蛋白酶体。
tirzepatide-内科杂志
肥胖症的流行率，因此，近几十年来，随着未来几年的这种趋势维持这种趋势。因此，迫切需要新的疗法来帮助我们修改这一轨迹。Tirzepatide, the first of a new pharmacological class called co-agonists or double agonists of glucagon--like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), demonstrated in clinical trials published in the last two years, significantly reduce blood glucose, to reduc to insulin resistance and reduce the insulin and reduce the insulin and reduce the resistance and reduce the insulin and reduce Body weight, with additional benefits in hypertension and lipid profile.预计其非血管终点的结果预计将是巨大的预期。在本文中，对这种药物进行了综述，以及在糖尿病和肥胖症治疗的未来中出现的观点。
董事会会议会议会议
几周前，我有机会在比尔·亨利希（Bill Henrich）的纪念和庆祝活动中参加U. T. Health Science Center -San Antonio。这是搬家的一天。我只想向董事会报告，在活动中，我代表董事会获得了荣誉，以宣布Henrich Family Care奖。An endowment that will provide in perpetuity a recognition and significant financial award to a member of the U. T. Health Science Center - San Antonio community who has demonstrated the qualities we all see in the Henrich Family.每年将向一名由同事提名的一名前线医疗保健工作者或表现出比尔，玛丽，约翰和艾米丽所反映的素质的患者，以富有同情心的同情和尊重。和我感谢董事会为U. T. Health Science Center -San Antonio提供了重要奖项。
肯尼亚的性别和可再生能源
能源部已经做出了良好的努力，以将性别纳入肯尼亚离网太阳能访问计划，最后一英里计划和沼气计划等项目。Building women's capacity as energy entrepreneurs and technicians, as demonstrated in a solar project in Homabay in western Kenya, effectively illustrated that adopting a gender and women's empowerment approach not only enabled women's active involvement in the energy supply and contributed to sales but also proved to have positive effects on increased self-esteem, helped to overcome traditional gender and social barriers as well as changing men's stereotypical and biased perceptions on women's角色和能力。'Homabay中的太阳能妈妈项目积极招募和训练妇女为技术人员。一些社区成员最初对将妇女瞄准该项目持怀疑态度。但是，这些妇女表现出色，以至于她们改变了男人对妇女在获得平等机会时能做和实现的态度。
ZM-8803是一种有效和选择性的SOS1 :: KRAS抑制剂，在Kras成瘾的癌症中有效
• Dysregulated MAPK signaling is implicated in multiple malignancies, such as RAS overactivation by mutation or/and upstream cues • SOS1/2 plays a key role in catalyzing the transformation of KRAS from inactive (GDP) to active (GTP-bound) form • Although KRAS G12C inhibition has demonstrated significant clinical benefits, resistance and disease progression occur in most patients • Furthermore, KRAS G12D和KRAS G12V比KRAS G12C更普遍，泛KRAS抑制剂将具有很高的临床价值•针对MAPK途径（垂直抑制）的不同步骤（例如，Braf Plus MEK抑制剂）在这里进行了很好的验证，在这里，我们报告了SOS1 Inighitor ZM-8803，作为一个型号，作为一个型号的表演，如PAN-8803，作为一个远母，作为一份远母，是一定的远母， KRAS突变肿瘤细胞体外和体内生长
Cadth报销建议
One international, double-blind, randomized, phase III study (TOPAZ-1) consisting of previously untreated adult patients with locally advanced or metastatic BTC demonstrated that treatment with durvalumab plus gemcitabine and cisplatin resulted in a statistically significant overall survival (OS) advantage compared to placebo plus gemcitabine and cisplatin (median OS, 12.9 months [95% CI, 11.6 to 14.1个月]与11.3个月[95％CI，10.1至12.5个月]，HR，0.76 [95％CI，0.64至0。91]）。在地标为12-（54.3％对47.1％），18-（34.8％对24.1％）和24.1％）和24个月（23.6％vs. 11.5％）的OS的其他分析支持了Durvalumab Plus Plus Gemcitabine和gemcitabine和cisplatin所证明的生存优势。durvalumab也与无进展生存率的改善有关（[PFS] HR，0.75 [95％CI，0.63至0.89]），并且没有其他严重的安全问题，可管理的毒性概况。TOPAZ-1试验的结果也表明HRQOL没有损害。